Introduction: Haemoglobin A 1c (HbA 1c ) is a key analyte for the monitoring of glycemic balance in diabetic patients and is used for diabetes diagnosis in many countries. The potential interference of carbamylated haemoglobin (cHb) and labile glycated haemoglobin (LA 1c ) on HbA 1c assays must remain a matter of vigilance. Such a situation has occurred in our laboratory with a kit replacement on the Bio-Rad Variant™ II testing system, a cation-exchange high performance liquid chromatography (HPLC) system. With this method, LA 1c and cHb coeluted in a same peak which may have different consequences on HbA 1c values.
Introduction
Since its discovery as unusual haemoglobin fraction in patients with diabetes mellitus, HbA 1c , the major component of glycated haemoglobin, has proved to be a useful analyte for the monitoring of glycemic balance in diabetic patients, and for diabetes diagnosis in many countries (1) (2) (3) . HbA 1c is also an important predictive marker of long term complications of diabetes (4, 5) . HbA 1c assays can be performed using different analytical principles including separative methods such as high performance liquid chromatography (HPLC) and capillary electrophoresis, but also immunological and enzymatic methods.
The quality of assay methods for HbA 1c determination has greatly improved over the last decades, and most of analytical interferences have been controlled (1, 6) . This is the case of carbamylated haemoglobin (cHb), which results from the binding of urea-derived isocyanic acid and is increased in patients with chronic kidney disease. However, the potential interference of cHb on HbA 1c assays must remain of matter of vigilance (7, 8) . Furthermore, interference may be caused by labile glycated haemoglobin (LA 1c ), a labile and reversible fraction (Schiff base) formed at early stages of glyca- Desmons A. et al. Interference of cHb and LA 1c on HbA 1c measurement tion reaction, which directly depends on blood glucose concentration. Such a situation is reported here.
We have recently changed the kit for HbA 1c determination in our laboratory, by replacing the NU Kit™ by the Dual Kit Program™ on the Bio-Rad Variant™ II testing system, based on cation-exchange HPLC. The analyser used for determination of HbA 1c is the same, but the chromatography program (column, buffer gradient) and the peak integration software (column, buffer gradient) are different. The main advantage of the method with the new kit is the possibility to use the same method for HbA 1c , haemoglobin A 2 , and haemoglobin F measurements.
Most frequent interferences encountered with such HPLC-based methods have been evaluated (9) . Whereas previous evaluations of this system did not report any interference studies (10), the instruction notes of the manufacturer mention a potential interference of cHb and LA 1c over 3%. Using the Dual kit program™, LA 1c and cHb coeluted in a same peak called LA 1c , contrary to the former program NU Kit™ which allowed the separation in two peaks. As these two minor Hb fractions coelute in a single peak before HbA 1c peak, the consequences on HbA 1c value may differ according to the increased fractions (cHb or LA 1c ). Indeed, besides reporting the differences of chromatographic separation of cHb and LA 1c between the two kits, the aim of this study was to evidence that the influence of cHb or LA 1c on HbA 1c measurements remains a critical issue and to propose a decision tree for managing these interferences in routine practice with this method. 
Materials and methods

Subjects
Statistical analysis
In vitro glycation or carbamylation experiments were analysed in triplicate. Results were expressed as means.
Relative and absolute biases were obtained with following formulas: Uncertainty measurement (U) was calculated using the following formulas:
where IQC represents internal quality control, EQE external quality control, CV coefficient of variation, m represents the mean; x lab laboratory result; x ref reference value.
The measurement uncertainty of the Variant II™system, calculated with the above formulas and equal to 0.3%, was used as a threshold to determine a significant difference between HbA 1c results.
Results
First, we studied the influence of increasing LA 1c values on HbA 1c results, and showed that the increase of LA 1c peak led to a decrease of HbA 1c values (Table 1) , the threshold of 0.3% being used as acceptance criterion to determine a significant difference between HbA 1c results. Thus, a significant interference was noticed when LA 1c exceeded 4%. Second, we studied the influence of cHb interference and found a significant interfering effect when cHb exceeded 2% (Table 2) .
Thus, both LA 1c and cHb interfered with HbA 1c determination, but it was noteworthy that the influence of the peak recognized as LA 1c on chromatogram depended on the nature of the interference. When the interference was caused by cHb, HbA 1c decrease was more prominent than when caused by LA 1c . For example, for an initial level of HbA 1c equal to 5.2% (33 mmol/mol) with a LA 1c peak at 1.2%, the increase of LA 1c peak to 3.4 % due to glycation (LA 1c increase) led to a decrease of HbA 1c value to 4.9% (30 mmol/mol), whereas it was 4.4% (25 mmol/mol) when the interference was due to carbamylation (cHb). Similar results were found using a sample with initial HbA 1c value of 8.1% (65 mmol/ mol): a decrease of HbA 1c to a value at 7.7% (61 mmol/mol) was observed for a cHb value of 2.2% whereas it was observed only at 4.6% of LA 1c (Tables  1 and 2 ). The impact of cHb and LA 1c on the HbA 1c measurements (Tables 1 and 2 ) was also highlighted using a graphical presentation (Figure 1 ).
Interestingly, we observed that chromatograms differed regarding retention time (higher for cHb than for LA 1c ) and peak shape depending on the origin of the interference (LA 1c or cHb), even though the peak was only recognized as LA 1c by the software (Figure 2 ). (11) . Because uraemia is the main cause of increased carbamylation (12) , and consequently of cHb formation, samples from 7 patients with increased blood urea (> 7.15 mmol/L) were assayed by both methods. Negative absolute and relative biases were evidenced in all samples with increased blood urea. Mean relative and absolute biases calculated were -8.2% and -5 mmol/L (-0.5%), respectively (Table 3) . By contrast, a similar comparison performed in samples from patients without hyperuraemia (urea < 7.15 mmol/L) showed mean relative and absolute biases equal to + 0.9% and +1.1 mmol/mol (+ 0.1%) respectively (Table 4) .
Discussion
Because HbA 1c is widely used for the diagnosis of diabetes and the monitoring of diabetic patients, its quantification must be performed using robust and high quality methods (2) . HPLC is commonly used for assaying HbA 1c , and the potential interferences, like those generated by LA 1c and cHb, have generally been well described. However, these additional Hb fractions may still cause unexpected interferences (7, 8, 13) . A previous study investigating the influence of cHb to HbA 1c measurements by Bio-Rad Variant II™ analyser equipped with NU Kit™ did not evidence such an impact of cHb but recommended an interpretation with caution when cHb was increased (14) .
Using the Dual kit program™, LA 1c and cHb coeluted in a same peak called LA 1c , contrary to the former program NU Kit™ which allowed the separation in two peaks. This peak which elutes just before HbA 1c peak could represent a potential interference on HbA 1c quantification. Thus, we have decided to apply different thresholds depending on the nature of the interference, according to decision tree shown in Figure 3 . For differentiating the origin of the interference, we consider (i) the retention time, (ii) the shape of the peak, and (iii) other biological results, especially uraemia. If the peak recognized as "LA 1c " is mainly formed by LA 1c, we consider that there is no interference until 4% of LA 1c . When LA 1c is increased over 4%, this fraction is eliminated by incubation of red blood cells for 30 minutes at 37 °C, according to a previously described procedure (16) . If the peak is mainly formed by cHb, we consider a lower interference threshold of 2%. When cHb values are higher than 2%, as cHb cannot be eliminated, we do not release values obtained by the HPLC method and perform HbA 1c assay using an immunological method, such as on DCA Vantage  System, not influenced by cHb.
Conclusion
This article reminds that cHb remains a critical issue in chromatography-based HbA 1c assays. The experimental verifications performed upon implementation of the method in our laboratory led us to change our practice, considering the coelution in a single peak of LA 1c and cHb. For that reason, the use of different thresholds (2% or 4% of LA 1c peak) has been established in our daily practice.
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